TransMedics (TMDX) Preferred Stock Liabilities (2018 - 2019)

TransMedics (TMDX) recorded quarterly Preferred Stock Liabilities of $186.5 million in Q1 2019, little changed quarter-over-quarter from $186.5 million in Q4 2018.

TransMedics (TMDX) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

TransMedics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $186.5 million for Q1 2019.

  • In Q1 2019, Preferred Stock Liabilities changed N/A year-over-year to $186.5 million; the TTM figure through Mar 2019 stood at $186.5 million (changed N/A YoY), while the FY2018 annual figure was $186.5 million, changed N/A from the prior year.
  • Preferred Stock Liabilities was $186.5 million for Q1 2019 at TransMedics, roughly flat from $186.5 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $186.5 million in Q4 2018 to a low of $186.5 million in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn -
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn -
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn -
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn -
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn -
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn -
10 TransMedics 2.72 Bn 2.26 Bn 101.16 Mn -

Historic Data

Download Data
DateValue
Mar 30, 2019 186.52 Mn
Dec 29, 2018 186.52 Mn